Company Overview and News

 
STOR / STORE Capital Corp. DEF 14A

1h sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A

 
STOR / STORE Capital Corp. DEFA14A

1h sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pur

 
Real Estate Earnings Preview: 5 Trends We're Watching

2018-04-18 seekingalpha
Earnings season kicks off this week in the real estate sector. 2018 has not been kind to the sector. REITs and homebuilders have each dipped nearly 9% YTD.

 
Ventas Is Not A Strong Buy

2018-04-14 seekingalpha
Ventas is a well-run company which has handily outperformed the broader market. And I do mean handily.

1
Don't Ever Fall In Love With Your Stocks

2018-04-06 seekingalpha
Forget your cost basis, and ask the question: if you had to buy this today, would you?

 
The More It Drops, The More I Buy

2018-04-02 seekingalpha
The REIT market continues to sell off – hitting new lows almost on a weekly basis.

 
Looking At Dividend Stocks For 2018

2018-03-31 seekingalpha
REITs are out of favor from the market, some of them are trading at excellent bargains.

 
STOR / STORE Capital Corp. PRE 14A

2018-03-30 sec.gov
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A

 
I Like What This STORE Is Selling

2018-03-30 seekingalpha
A stock backed by one of the most famous investors of all time, Warren Buffett, who purchased shares in June 2017.

 
You Can't Double Down If You Don't Know What You're Holding

2018-03-30 seekingalpha
With stocks as volatile as ever, this is a good opportunity to tidy up our portfolios.

 
A Growing Dividend Portfolio That Will Survive Rising Interest Rates

2018-03-28 seekingalpha
By combining stocks from many different industries, we mitigate risk (as opposed to owning say, all REITs).

1
When You're A Landlord And Tenant, Investors Lose

2018-03-27 seekingalpha
Sometimes it’s important to check closely under the hood before purchasing shares in any company that seems too good to be true.

 
Beware Of These 'Sucker Yields': The Bracket Buster Edition

2018-03-22 seekingalpha
Finding the right REIT at the right price – with a margin for safety against unknown market risk – is the ultimate goal.

 
Nick's Portfolio Tournament First Round Results

2018-03-19 seekingalpha
Alright basketball fans and portfolio managers, here we have it: the first round results of the 2018 Nick's Portfolio Tournament. For those of you who missed it, I said out the selection committee's decision in this introductory piece a week ago. First of all, let me preface this piece by saying that this was a bit of a marathon type-fest, so I ask that you please forgive any typos ahead of time. Secondly, I want to re-hash the competition criteria.

 
March Madness: Nothing But Net

2018-03-19 seekingalpha
I doubt think you’ll see any busted brackets today in the net lease sector, and remember, free throws can will the game!

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 862121100